Business Context and Reporting Period
Company: TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.)
Reporting Period: Quarter ended September 30, 2024 (Q3 2024)
Business Overview: A clinical-stage biopharmaceutical company focused on developing MYMD-1 (an oral TNF-α inhibitor for sarcopenia and autoimmune diseases) and Supera-CBD (a synthetic CBD analog). The company has no product revenue and relies on financing to fund operations.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1,929,391) | $4,042,994 (Income) | $(21,295,080) | $(1,636,391) |
| Net Loss Attributable to Common Stockholders | $(2,680,443) | $2,884,943 | $(24,025,339) | $(3,326,571) |
| Operating Expenses | $1,825,639 | $3,842,588 | $7,979,907 | $12,214,539 |
| Cash and Cash Equivalents (End of Period) | $1,192,351 | $298,318 | $1,192,351 | $298,318 |
| Marketable Securities (End of Period) | $9,449,483 | $2,242,106 | $9,449,483 | $2,242,106 |
| Total Current Assets | $12,026,935 | $5,816,342 | $12,026,935 | $5,816,342 |
| Total Current Liabilities | $6,988,723 | $4,988,089 | $6,988,723 | $4,988,089 |
| Working Capital | $5,038,212 | $828,253 | $5,038,212 | $828,253 |
| Stockholders' Equity | $16,777,343 | $15,500,682 | $16,777,343 | $15,500,682 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased significantly in Q3 2024 compared to Q3 2023 ($1.83M vs. $3.84M). This reduction is primarily due to decreased personnel costs (employee reductions in late 2023) and lower R&D spend following the completion of the Phase II sarcopenia study in 2023.
- Net Income/Loss Volatility: The company reported a net loss of $1.93M in Q3 2024, contrasting with a net income of $4.04M in Q3 2023. The 2023 income was driven by a $7.9M non-cash gain from the change in fair value of warrant liabilities. In Q3 2024, this was replaced by a $356k loss on derivative liabilities and a $17k loss on warrant liabilities.
- Financing Activity: During the nine months ended September 30, 2024, the company raised approximately $14.0M in net proceeds from the issuance of Series F-1 and Series G Convertible Preferred Stock. This contrasts with the prior year period where financing was driven by the Series F offering.
- Balance Sheet: Total assets increased to $24.0M from $17.9M at year-end 2023, driven by an increase in marketable securities ($9.45M vs. $2.24M). However, current liabilities also rose to $7.0M, largely due to accrued dividends payable ($1.5M) and derivative liabilities ($1.3M).
Guidance, Outlook, Risks, and Unusual Items
- Liquidity Outlook: Management believes current resources (cash and marketable securities totaling ~$10.6M) are sufficient to fund operations for the next 12 months. However, the company has an accumulated deficit of $126.0M and continues to burn cash.
- Preferred Stock Obligations: The company has significant obligations related to Series F, F-1, and G Preferred Stock. These instruments carry 10% annual dividends (15% upon triggering events) and require monthly installment redemptions. Payments can be made in cash or stock, creating a risk of substantial dilution if paid in stock or cash depletion if paid in cash.
- Unusual Items:
- Non-Cash Losses: The YTD 2024 net loss includes significant non-cash charges: $8.8M loss on issuance of preferred stock (due to warrant fair value exceeding proceeds), $4.4M loss on change in fair value of warrant liabilities, and $367k loss on derivative liabilities.
- Insurance Settlement: The company recorded a $100,000 gain from an insurance settlement for a casualty loss that occurred in July 2023.
- Risks:
- Dilution: Full ratchet anti-dilution provisions in preferred stock and warrants could significantly lower conversion/exercise prices in future financings, increasing the number of shares issuable.
- Regulatory: Success depends on FDA approval for MYMD-1 and Supera-CBD. No revenue is expected until commercialization.
- Legal: Ongoing litigation with Raymond Akers regarding whistleblower claims is in the discovery phase.
Investor Verification Checklist
- Preferred Stock Terms: Verify the specific redemption schedules and dividend accrual rates for Series F, F-1, and G Preferred Stock to assess immediate cash burn or dilution risk.
- Warrant Liability Reclassification: Confirm the impact of the recent warrant amendments (Series F, F-1, G) that reclassified liabilities to equity, and monitor for future fair value adjustments.
- Cash Runway: Validate the $10.6M liquidity position against the monthly burn rate, considering the potential need to pay preferred dividends in cash if stock price conditions are not met.
- Anti-Dilution Provisions: Review the "full ratchet" clauses in the preferred stock agreements to understand the potential dilution impact of any future equity raises below current conversion prices.
- Legal Proceedings: Monitor the status of the Raymond Akers litigation for potential settlement costs or adverse rulings.